2-甲基-2-丙基(3S,4R)-3-氨基-4-羟基-1-吡咯烷羧酸酯 | 190792-75-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 2-甲基-2-丙基(3S,4R)-3-氨基-4-羟基-1-吡咯烷羧酸酯
• 中文别名: 叔-丁基(3S,4R)-3-氨基-4-羟基吡咯烷-1-甲酸基酯；2-吡咯烷酮,4-羟基-3,3-二甲基-5-(1-甲基乙基)-,(5S)-
• 英文名称: (3R,4S)-4-amino-1-N-tert-butyloxycarbonyl-3-hydroxypyrrolidine
• 英文别名: tert-butyl (3S,4R)-3-amino-4-hydroxypyrrolidine-1-carboxylate
• CAS: 190792-75-7
• 化学式: C₉H₁₈N₂O₃
• 分子量: 202.254
• InChiKey: MOZOQDNRVPHFOO-NKWVEPMBSA-N

物化性质

• 沸点：
  308.8±42.0 °C(Predicted)
• 密度：
  1.179±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  75.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-甲基-2-丙基(3S,4R)-3-氨基-4-羟基-1-吡咯烷羧酸酯 在 三乙胺 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 9.0h， 生成 (3S,4S)-trans-N-Boc-3-acetylthio-4-(4-phenoxybenzenesulfonamido)pyrrolidine
  参考文献：
  名称：

  Matrix Metalloproteinase Inhibitors Based on the 3-Mercaptopyrrolidine Core

  摘要：

  New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamidopyrrolidine matrix metalloproteinase inhibitors (MMPIs) were designed, synthesized, and evaluated. Exhibiting unique properties over other MMPIs (e.g., hydroxamates), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (similar to 2 to 50 nM), MMP-13 (similar to 2 to 50 nM), and MMP-14 (similar to 4 to 60 nM). Additionally these compounds are selective to intermediate- and deep-pocket MMPs but not shallow-pocketed MMPs (e.g., MMP-1, similar to 850 to >50 000 nM; MMP-7, similar to 4000 to >25 000 nM). Our previous work with the mercaptosulfide functionality attached to both cyclopentane and pyrrolidine frameworks demonstrated that the cis-(3S,4R)-stereochemistry was optimal for all of the MMPs tested. However, in our newest compounds an interesting shift of preference to the trans form of the mercaptosulfonamides was observed with increased oxidative stability and biological compatibility. We also report several kinetic and biological characteristics showing that these compounds may be used to probe the mechanistic activities of MMPs in disease.

  DOI：

  10.1021/jm400529f
• 作为产物：
  描述：

  N-Boc-3-吡咯啉 在 甲醇 、 sodium azide 、 乙酸异丙烯酯 、 lipase Amano AK-20 、 水 、 氯化铵 、 三乙胺 、 间氯过氧苯甲酸 、 三苯基膦 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 甲基叔丁基醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 78.0h， 生成 2-甲基-2-丙基(3S,4R)-3-氨基-4-羟基-1-吡咯烷羧酸酯
  参考文献：
  名称：

  Matrix Metalloproteinase Inhibitors Based on the 3-Mercaptopyrrolidine Core

  摘要：

  New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamidopyrrolidine matrix metalloproteinase inhibitors (MMPIs) were designed, synthesized, and evaluated. Exhibiting unique properties over other MMPIs (e.g., hydroxamates), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (similar to 2 to 50 nM), MMP-13 (similar to 2 to 50 nM), and MMP-14 (similar to 4 to 60 nM). Additionally these compounds are selective to intermediate- and deep-pocket MMPs but not shallow-pocketed MMPs (e.g., MMP-1, similar to 850 to >50 000 nM; MMP-7, similar to 4000 to >25 000 nM). Our previous work with the mercaptosulfide functionality attached to both cyclopentane and pyrrolidine frameworks demonstrated that the cis-(3S,4R)-stereochemistry was optimal for all of the MMPs tested. However, in our newest compounds an interesting shift of preference to the trans form of the mercaptosulfonamides was observed with increased oxidative stability and biological compatibility. We also report several kinetic and biological characteristics showing that these compounds may be used to probe the mechanistic activities of MMPs in disease.

  DOI：

  10.1021/jm400529f

文献信息

• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS DE TYROSINE KINASE DE BRUTON ET LEURS PROCÉDÉS D'UTILISATION
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018103058A1

  公开（公告）日：2018-06-14

  Compounds of formula (I') and methods of their use and preparation, as well as compositions comprising compounds of formula (I').

  公式（I'）的化合物及其使用和制备方法，以及包含公式（I'）化合物的组合物。
• [EN] Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection<br/>[FR] NOUVEAUX COMPOSÉS PYRIDO[2,3-B]INDOLE POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION BACTÉRIENNE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018178041A1

  公开（公告）日：2018-10-04

  The present invention relates to novel compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

  本发明涉及式(I)的新化合物，其中R1、R2、R3、R4、R5和R6如本文所述，以及它们的药用盐、对映体或二对映体，以及包括这些化合物的组合物和使用这些化合物的方法。
• Cyclic amines
  申请人：Zbinden Groebke Katrin

  公开号：US20060247238A1

  公开（公告）日：2006-11-02

  The invention is concerned with cyclic amines of formula (I) wherein X 1 to X 3 , Y 1 to Y 3 , R 1′ , R 1″ and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit coagulation factor Xa and can be used as medicaments and for treating diseases associated with coagulation factor Xa.

  这项发明涉及公式(I)中的环氨基化合物，其中X1至X3，Y1至Y3，R1'，R1"和n如描述和索赔中定义的那样，以及其生理上可接受的盐。这些化合物抑制凝血因子Xa，并可用作药物治疗与凝血因子Xa相关的疾病。
• Nicotinamide Derivatives
  申请人：Blake Tanisha D.

  公开号：US20080146569A1

  公开（公告）日：2008-06-19

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.

  本发明涉及公式（I）的化合物及其药用可接受的盐和溶剂化合物，其中取代基如本文所定义，包含这种化合物的组合物以及这种化合物用于治疗各种疾病和状况，如哮喘。
• [EN] COVALENT INHIBITORS OF PAD4<br/>[FR] INHIBITEURS COVALENTS DE PAD4
  申请人：PADLOCK THERAPEUTICS INC

  公开号：WO2018022897A1

  公开（公告）日：2018-02-01

  The present invention provides compounds of formula I useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

  本发明提供了一种公式I的化合物，其可用作PAD4的抑制剂，以及其组合物和治疗PAD4相关疾病的方法。